30 January 2020
EMA/CHMP/15190/2020
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (initial authorisation)

Liumjev

insulin lispro

On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Liumjev, intended for the treatment of diabetes mellitus in adults.

The applicant for this medicinal product is Eli Lilly Nederland B.V.

Liumjev will be available as solution for injection (100 units/ml and 200 units/ml). The active substance of Liumjev is insulin lispro, a fast-acting insulin analogue (ATC code: A10AB04) which is absorbed more rapidly by the body and can therefore act faster than injected human insulin.

The benefits with Liumjev are its ability to control blood glucose levels. The most common side effect is hypoglycaemia.

The full indication is: "Treatment of diabetes mellitus in adults".

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union